A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe psoriasis in a head-to-head randomized trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/novel-oral-il-23-inhibitor-superior-jak-inhibitor-psoriasis-2025a1000ppj?src=rss
Author :
Publish date : 2025-09-25 13:35:00
Copyright for syndicated content belongs to the linked Source.
